G+FLAS Life Sciences

Company Snapshot

Founded: 2014
Entity Type: Private
Region: Republic of Korea
Headquarter: Chungcheongbuk-do, Republic of Korea
Key Geographics: Republic of Korea, U.S.
Corporate Address: 123, Uiryodanji-gil, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea Tel: +82-043-236-2201 www.gflas.com

Company Overview

Founded in 2014, G+Flas Life Sciences Inc. develops CRISPR/Cas genome-editing technologies for a range of applications, including gene-therapy drugs, biopharmaceuticals and agriculture.

In October 2018, G+Flas launched CRISPR-Plus (proprietary MgCas12a) and CRISPR/Cas9 monoclonal antibody products.

G+Flas also markets technology tools for delivering gene-editing ribonucleoprotein constructs into plant protoplasts.

G+FLAS Life Sciences In Reports

Synthetic Biology: Global Markets

BCC Research Market Report for synthetic biology is estimated to increase from $9.5 billion in 2021 to $33.2 billion by 2026, at a compound annual growth rate of 28.4%

Agricultural Biotechnology: Emerging Technologies and Global Markets

The global market for agricultural biotechnology products should grow from $50.5 billion in 2019 to $72.2 billion by 2024 with a compound annual growth rate (CAGR) of 7.4% for the period of 2019-2024.

Synthetic Biology: Global Markets

The global synthetic biology market should grow from $5.3 billion in 2019 to $18.9 billion by 2024 with a compound annual growth rate (CAGR) of 28.8% for the period of 2019-2024.

Company's Business Segments

  • Products : CRISPR Genome Editing, CRISPR PLUSTM Gene Editing Tools, Technology for Delivering Gene Editing Molecular Scissors into plant protoplasts
  • Services : Non-GMO Plant Transformation, Plant-based 'trastuzumab' biosimilar antibody, Cas9 monoclonal antibody, Host plants with glycotechnology, Others

Applications/End User Industries

  • Biotechnology
  • Pharmaceuticals
  • Healthcare
  • Oncology
  • Agriculture
  • Academic and Research
  • Life Sciences
AI Sentiment